Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats

Bone

Volumn 42, Issue 1, 2008, Pages 90-97

  Nozaka, Koji ^a   Miyakoshi, Naohisa ^a   Kasukawa, Yuji ^a   Maekawa, Shigeto ^a   Noguchi, Hideaki ^a   Shimada, Yoichi ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marrow cells; Bone union; Cancellous bone; Osteotomy; Parathyroid hormone

Indexed keywords

CELL NUCLEUS ANTIGEN; PARATHYROID HORMONE[1-34];

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCELLOUS BONE; CELL KINETICS; CELL PROLIFERATION; CELL VOLUME; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; FEMALE; FRACTURE HEALING; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE TRANSFORMATION; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOTOMY; OVARIECTOMY; RAT; SHAM PROCEDURE; TIBIA; TIBIA PROXIMAL OSTEOTOMY; TREATMENT DURATION;

ADIPOCYTES; ANIMALS; BONE AND BONES; BONE DENSITY; FATS; FEMALE; HUMANS; OSTEOGENESIS; OSTEOTOMY; OVARIECTOMY; PARATHYROID HORMONE; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, WISTAR;

EID: 37349103446     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.08.041     Document Type: Article

References (55)

1. Lemke D.M. Vertebroplasty and kyphoplasty for treatment of painful osteoporotic compression fractures. J Am Acad Nurse Pract 17 (2005) 268-276
2. Ring D., Kloen P., Kadzielski J., Helfet D., and Jupiter J. Locking compression plates for osteoporotic nonunions of the diaphyseal humerus. Clin Orthop Relat Res 425 (2004) 50-54
3. Petersen M.M., Gehrchen P.M., Nielsen P.K., and Lund B. Loss of bone mineral of the hip assessed by DEXA following tibial shaft fractures. Bone 20 (1997) 491-495
4. Findlay S.C., Eastell R., and Ingle B.M. Measurement of bone adjacent to tibial shaft fracture. Osteoporos Int 13 (2002) 980-989
5. Pankovich A.M., and Tarabishy I.E. Ender nailing of intertrochanteric and subtrochanteric fractures of the femur. J Bone Joint Surg Am 62 (1980) 635-645
6. Wenzl M.E., Porte T., Fuchs S., Faschingbauer M., and Jurgens C. Delayed and non-union of the humeral diaphysis-compression plate or internal plate fixator?. Injury 35 (2004) 55-60
7. Miyakoshi N. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr Pharm Des 10 (2004) 2615-2627
8. Body J.J., Gaich G.A., Scheele W.H., Kulkarni P.M., Miller P.D., Peretz A., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87 (2002) 4528-4535
9. Sato M., Ma Y.L., Hock J.M., Westmore M.S., Vahle J., Villanueva A., et al. Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment. J Pharmacol Exp Ther 302 (2002) 304-313
10. Tsuchida T., Miyakoshi N., Kudo T., Tamura Y., Kasukawa Y., Suzuki K., et al. Restoring effect of human parathyroid hormone (1-34) on trabecular connectivity in ovariectomized rats. Tohoku J Exp Med 194 (2001) 213-221
11. Tsuchida T., Sato K., Miyakoshi N., Abe T., Kudo T., Tamura Y., et al. Histomorphometric evaluation of the recovering effect of human parathyroid hormone (1-34) on bone structure and turnover in streptozotocin-induced diabetic rats. Calcif Tissue Int 66 (2000) 229-233
12. Bringhurst F.R. PTH receptors and apoptosis in osteocytes. J Musculoskelet Neuronal Interact 2 (2002) 245-251
13. Kasukawa Y., Miyakoshi N., Itoi E., Tsuchida T., Tamura Y., Kudo T., et al. Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy. J Orthop Res 22 (2004) 457-464
14. Alkhiary Y.M., Gerstenfeld L.C., Krall E., Westmore M., Sato M., Mitlak B.H., et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87 (2005) 731-741
15. Komatsubara S., Mori S., Mashiba T., Nonaka K., Seki A., Akiyama T., et al. Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 36 (2005) 678-687
16. Loveridge N., Power J., Reeve J., and Boyde A. Bone mineralization density and femoral neck fragility. Bone 35 (2004) 929-941
17. Suzuki K., Miyakoshi N., Tsuchida T., Kasukawa Y., Sato K., and Itoi E. Effects of combined treatment of insulin and human parathyroid hormone(1-34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats. Bone 33 (2003) 108-114
18. Tamura Y., Miyakoshi N., Itoi E., Abe T., Kudo T., Tsuchida T., et al. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. J Bone Miner Res 16 (2001) 541-549
19. Abe T., Sato K., Miyakoshi N., Kudo T., Tamura Y., Tsuchida T., et al. Trabecular remodeling processes in the ovariectomized rat: modified node-strut analysis. Bone 24 (1999) 591-596
20. Kim H.J., Bae Y.C., Park R.W., Choi S.W., Cho S.H., Choi Y.S., et al. Bone-protecting effect of safflower seeds in ovariectomized rats. Calcif Tissue Int 71 (2002) 88-94
21. Seto H., Aoki K., Kasugai S., and Ohya K. Trabecular bone turnover, bone marrow cell development, and gene expression of bone matrix proteins after low calcium feeding in rats. Bone 25 (1999) 687-695
22. Gittens S.A., Wohl G.R., Zernicke R.F., Matyas J.R., Morley P., and Uludag H. Systemic bone formation with weekly PTH administration in ovariectomized rats. J Pharm Pharm Sci 7 (2004) 27-37
23. Okimoto N., Tsurukami H., Okazaki Y., Nishida S., Sakai A., Ohnishi H., et al. Effects of a weekly injection of human parathyroid hormone (1-34) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats. Bone 22 (1998) 523-531
24. Uzawa T., Hori M., Ejiri S., and Ozawa H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 16 (1995) 477-484
25. Nakajima A., Nakajima F., Shimizu S., Ogasawara A., Wanaka A., Moriya H., et al. Spatial and temporal gene expression for fibroblast growth factor type I receptor (FGFR1) during fracture healing in the rat. Bone 29 (2001) 458-466
26. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 (1987) 595-610
27. Honda A., Kurabayashi T., Yahata T., Tomita M., Matsushita H., Takakuwa K., et al. Effects of pregnancy and lactation on trabecular bone and marrow adipocytes in rats. Calcif Tissue Int 67 (2000) 367-372
28. Meunier P., Aaron J., Edouard C., and Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 80 (1971) 147-154
29. Iwaki A., Jingushi S., Oda Y., Izumi T., Shida J.I., Tsuneyoshi M., et al. Localization and quantification of proliferating cells during rat fracture repair: detection of proliferating cell nuclear antigen by immunohistochemistry. J Bone Miner Res 12 (1997) 96-102
30. Nakazawa T., Nakajima A., Shiomi K., Moriya H., Einhorn T.A., and Yamazaki M. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 37 (2005) 711-719
31. Reginster J.Y. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des 11 (2005) 3711-3728
32. Reginster J.Y., and Devogelaer J.P. Treatment of postmenopausal osteoporosis in 2004. Rev Med Liege 59 (2004) 633-647
33. Fink H.A., Ensrud K.E., Nelson D.B., Kerani R.P., Schreiner P.J., Zhao Y., et al. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int 14 (2003) 69-76
34. Cao Y., Mori S., Mashiba T., Westmore M.S., Ma L., Sato M., et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17 (2002) 2237-2246
35. Li C., Mori S., Li J., Kaji Y., Akiyama T., Kawanishi J., et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16 (2001) 429-436
36. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
37. Nakajima A., Shimoji N., Shiomi K., Shimizu S., Moriya H., Einhorn T.A., et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17 (2002) 2038-2047
38. Nakazawa T., Nakajima A., Shiomi K., Moriya H., Einhorn T.A., and Yamazaki M. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 37 (2005) 711-719
39. Dempster D.W., Cosman F., Parisien M., Shen V., and Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 14 (1993) 690-709
40. Nishida S., Yamaguchi A., Tanizawa T., Endo N., Mashiba T., Uchiyama Y., et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15 (1994) 717-723
41. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278 (2003) 50259-50272
42. Sowa H., Kaji H., Iu M.F., Tsukamoto T., Sugimoto T., and Chihara K. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts. J Biol Chem 278 (2003) 52240-52252
43. Ishizuya T., Yokose S., Hori M., Noda T., Suda T., Yoshiki S., et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99 (1997) 2961-2970
44. Miyakoshi N., Kasukawa Y., Linkhart T.A., Baylink D.J., and Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142 (2001) 4349-4356
45. Yamaguchi M., Ogata N., Shinoda Y., Akune T., Kamekura S., Terauchi Y., et al. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 146 (2005) 2620-2628
46. Chan G.K., Miao D., Deckelbaum R., Bolivar I., Karaplis A., and Goltzman D. Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1/2 mesenchymal cells. Endocrinology 144 (2003) 5511-5520
47. Martin R.B., Chow B.D., and Lucas P.A. Bone marrow fat content in relation to bone remodeling and serum chemistry in intact and ovariectomized dogs. Calcif Tissue Int 46 (1990) 189-194
48. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Prosteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278 (2003) 259-272
49. Lecka-Czernik B., Gubrij I., Moerman E.J., Kajkenova O., and Lipschit D.A. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 74 (1999) 357-371
50. Martin R.B., and Zissimos S.L. Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone 12 (1991) 123-131
51. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
52. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
53. Miki T., Nakatsuka K., Naka H., Masaki H., Imanishi Y., Ito M., et al. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment. J Bone Miner Metab 22 (2004) 569-576
54. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40 (2007) 1434-1446
55. Amizuka N., Oda K., Shimomura J., and Maeda T. Biological action of parathyroid hormone (PTH) related peptide (PTHrP) mediated either by the PTH/PTHrP receptor or the nucleolar translocation in chodrocytes. Anat Sci Int 77 (2002) 225-236